Nasdaq

Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
Yahoo Finance

MoSys Announces SAMPLE PROGRAM With Digi-Key Electronics for New QUAZAR QPR Product Line

MoSys QUAZAR devices achieve a cost point previously not attainable with memories at these speeds and densities. MoSys achieves this by utilizing its 1T memory cell and advanced memory architectures.
Nasdaq

MoSys Launches New QUAZAR QPR Family of Low Cost, Quad Partition Rate SRAM Memory ICs Targeted for Accelerating INTEL and XILINX FPGA Designs

QDR Level Performance - Replaces up to 8X QDRs - Capacities of 576Mb or 1Gb in Single Device Costing Less Than $200 in Volume Quantities SAN JOSE, CA / ACCESSWIRE / July 15, 2020 / MoSys, Inc. (NASDAQ ...
USA Today

New to The Street’s Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

CALABASAS, CA AND ABU DHABI, UAE / ACCESS Newswire / August 11, 2025 / NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for ...
Seeking Alpha

NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies ...